Colesevelam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hypercholesterolaemia; Adjunct to Type 2 DM 3.75 g/day in 1-2 divided doses. Max: 4.375 g/day. In combination w/ a statin w/ or w/o ezetimibe: 2.5-3.75 g/day.
Dosage Details
Oral
Adjunct to Type 2 diabetes mellitus, Hypercholesterolaemia
Adult: 3.75 g daily in 1-2 divided doses. Max: 4.375 g daily. In combination w/ a statin w/ or w/o ezetimibe: 2.5-3.75 g daily.
Administration
Should be taken with food.
Contraindications
History of bowel obstruction, serum triglyceride concentrations >500 mg/dL, history of hypertriglyceridemia-induced pancreatitis.
Special Precautions
Patient w/ triglyceride concentration >300 mg/dL, dysphagia or swallowing disorders, gastroparesis or other GI motility disorders. Patient susceptible to vit K deficiency (e.g. malabsorption syndromes) or other fat-soluble vit. Patient who underwent major GI tract surgery and who may be at risk for bowel obstruction. Pregnancy and lactation.
Adverse Reactions
Constipation, dyspepsia, nausea, accidental injury, asthenia, pharyngitis, flu-like syndrome, rhinitis, myalgia, hypoglycaemia. HTN, hypertriglyceridemia.
MonitoringParameters
Monitor lipid parameter, including serum triglyceride and non-HDL cholesterol concentrations prior to therapy and periodically thereafter.
Overdosage
Symptoms: Severe local GI effects (e.g. constipation). Management: Location and degree of obstruction, presence or absence of normal gut motility would determine treatment.
Drug Interactions
May decrease absorption of fat-soluble vit A, D, E and K. May interfere w/ anticoagulant effect of warfarin. May reduce serum concentration of ciclosporin, phenytoin, glibenclamide, ethinyl estradiol, norethindrone.
Action
Description: Colesevelam, a nonabsorbable hydrogel, binds w/ bile acids in the intestine to form a nonabsorbable complex that is excreted in the faeces. This results in increased conversion of cholesterol to bile acids in the liver causing a compensatory increase in hepatic uptake of circulating LDL cholesterol.
Onset: Approx 2 wk.
Pharmacokinetics:
Absorption: Not absorbed from the GI tract.
Excretion: Via urine (0.05%).
Storage
Store at 25°C. Protect from moisture.
References
Anon. Colesevelam. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/10/2014.

Buckingham R (ed). Colesevelam Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Colesevelam Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/10/2014.

Welchol Film-Coated Tablet, Suspension (Daiichi Sankyo, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/10/2014.

Welchol Tablets. U.S. FDA. https://www.fda.gov/. Accessed 02/10/2014.

Disclaimer: This information is independently developed by MIMS based on Colesevelam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in